The status quo
For decades, clinical trials have represented both the promise and the challenge of modern medicine. They are where bold scientific ideas meet the realities of patient care, yet they are also where over 90% of promising therapies fail. Recruitment remains one of the greatest obstacles—finding the right patients at the right time, under the right conditions. Too often, trials launch with optimism only to falter because eligible patients are difficult to identify or because competing studies chase the same small populations.
This is more than a logistical hurdle. It is a systemic barrier that slows innovation, increases costs, and delays access to therapies for patients in need.
AI as the catalyst
Innovation is a strategic priority at WWT, and that extends to the healthcare and life science industries. By harnessing AI, it's possible to reimagine how patients and trials are brought together—not as a tedious, manual process, but as a streamlined, data-driven system that benefits patients, providers and sponsors alike.
Picture a physician who can instantly identify eligible patients without combing through hundreds of pages of criteria. A sponsor who can evaluate trial feasibility before investing millions. Or a biopharma company that can see overlapping studies and plan smarter across its portfolio.
These are no longer futuristic scenarios; they are capabilities demonstrated today. WWT's work in this space shows how advanced AI models, applied to synthetic patient data and publicly available trial records, can surface insights in seconds that once took weeks. It is about more than efficiency; it is about clarity, foresight and opportunity.
For IT and life science leaders, the message is clear: AI is not a peripheral tool—it is a catalyst. It shortens timelines, reduces costs and, most importantly, helps deliver therapies to patients faster. In an industry where every month matters, that acceleration can mean the difference between a promising idea and a transformative treatment.
Getting started
WWT brings together the technical expertise and industry understanding needed to make this vision real. We see AI not as an abstract experiment, but as a strategic enabler—one that connects the science of discovery with the systems that support it. From selecting the right high-performance architecture to implementing the right data strategy to hosting custom lab environments in our AI Proving Ground (AIPG) we help our life science clients turn AI from concept into competitive advantage.
The question for executives is no longer if AI can transform clinical trial recruitment. It's how quickly organizations will embrace it—and how far ahead they'll be when they do.
